ArticleFood science & nutrition2020
miRNA-216 knockdown has effects to suppress osteosarcoma via stimulating PTEN.
Article in Food science & nutrition, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Harnessing natural compounds and nanotechnology for miRNA-based osteosarcoma therapy.RSC advances · 2026Review
- NFATC3 enhances osteosarcoma progression by increasing PD-L1 and CXCL2 levels.Medical oncology (Northwood, London, England) · 2025Article
- Functional role of MicroRNA/PI3K/AKT axis in osteosarcoma.Frontiers in oncology · 2023Review
- Mechanical strain regulates osteoclastogenesis via modulating the PTEN/PI3K/Akt signal pathway through miR-21.Cytotechnology · 2022Article
- MiR-195-5p Ameliorates Cerebral Ischemia-Reperfusion Injury by Regulating the PTEN-AKT Signaling Pathway.Neuropsychiatric disease and treatment · 2021Article
- miRNA-216 knockdown has effects to suppress osteosarcoma via stimulating PTEN.Food science & nutrition · 2020Article
- Advances in the Biological Functions and Mechanisms of miRNAs in the Development of Osteosarcoma.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to explain the effects and mechanism of miRNA-216 in osteosarcoma. We firstly evaluated the PTEN expression in 30 pairs of tumor and adjacent tissues which were from the 30 osteosarcoma patients. In the following cell experiments, we measured the cell proliferation, cell cycle, cell invasion, and migration abilities of NC (normal control) group, BL (blank) group, siRNA (miRNA-216 inhibitor) group, and siRNA+PTEN inhibitor group. Furthermore, we measured the relative protein expression of difference groups by WB to explain the mechanism of miRNA-216 in osteosarcoma. The PTEN was confirmed the target gene of miRNA-216 by double luciferase target test. In conclusion, miRNA-216 was an oncogene in osteosarcoma. miRNA-216 knockdown had effects to suppress cancer cell proliferation, invasion and migration and improve cell apoptosis by keeping in G1 phase via PTEN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.